Pharmaceuticals
GT Apeiron Therapeutics Strengthens Advisory Board
SHANGHAI, April 16, 2021 /PRNewswire/ -- Keith Lenden and Dr. Honggang Bi has been appointed as new members of the Advisory Board at GT Apeiron Therapeutics, an AI empowered drug discovery start-up developing oncology therapeutics. Mr. Lenden and Dr. Bi add further expertise in drug discovery inn...
Juniper Biologics Announces the Appointment of Raman Singh as Chief Executive
SINGAPORE, April 15, 2021 /PRNewswire/ -- Juniper Biologics, a science-led healthcare company focused on researching, developing & commercialising novel therapies, has announced the appointment of celebrated pharmaceutical executive Raman Singh to the role of Chief Executive. Juniper Biologics wi...
New clinical study shows JOYSBIO COVID-19 neutralizing antibody rapid test nearly 98% accurate in verifying antibodies after vaccination
TIANJIN, China, April 15, 2021 /PRNewswire/ -- In a major breakthrough for testing COVID-19 immunity, JOYSBIO, a Chinese medical device manufacturer, just announced the completion of a clinical study inItaly, showing their COVID-19 neutralizing antibody rapid test kit is 98.05% effective in detec...
Seegene's Italy subsidiary secures public procurement for 7.15 million COVID-19 diagnostic tests, the largest tender in history
* Seegene's Italian subsidiary to supply some 7.15 million COVID-19 tests to 17 regions there * S. Korean biotechnology firm to expand its influence in Italy's PCR diagnostic industry SEOUL, South Korea, April 15, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a leading molecular diagnostics ...
Everest Medicines Appoints Jennifer Yang as Chief Scientific Officer
SHANGHAI, April 15, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces that the US FDA has Granted Licensing Partner Gilead Sciences, Inc. Accelerated Approval of Trodelvy® for the Treatment of Metastatic Urothelial Cancer
SHANGHAI, April 14, 2021 /PRNewswire/ -- Everest Medicines
Gannex Announces the First Cohort Dosed in a U.S. Clinical Study with THR-β Agonist ASC41
SHANGHAI, April 14, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), today announces the dosing of the first cohort in the U.S. Phase I cli...
BioVaxys Announces Final Clinical trial results of HPV product from EU partner ProCare Health Iberia published by American Society for Colposcopy and Cervical Pathology
VANCOUVER, BC, April 14, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:LMNGF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancers applications, is pleased to announce the results of a clinical study conducted by ProCare Health Iberia...
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery
SINGAPORE, April 14, 2021 /PRNewswire/ -- Moleac, a biopharmaceutical company based inSingapore, announced the approval by the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for MLC1501 in traumatic brain injury (TBI). Moleac is dedicated in finding, dev...
Psychobiotic PS128 improves mood and sleep quality in its first clinical study on anxiety and stress
TAIPEI, April 13, 2021 /PRNewswire/ -- Bened Biomedical's psychobiotic PS128 significantly improved insomnia, stress, and anxiety during a recent clinical trial. Participants were IT professionals under high levels of work-life stress. Psychobiotics are probiotics that yield specific mental healt...
Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL
SHANGHAI, China and GAITHERSBURG, U.S., April 13, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in h...
Ascletis Announced Four Clinical and Preclinical Study Abstracts of NASH and HBV Accepted as Poster Presentations by the International Liver Congress™ 2021
HANGZHOU, China and SHAOXING, China, April 12, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) announces today that four clinical and preclinical study abstracts of NASH and HBV have been accepted by the International Liver Congress™ 2021 as poster presentations. The summary of the four abs...
Antengene Announces First Patient Dosed in Phase II Trial of ATG-008 (Onatasertib) in Patients with Advanced Solid Tumors with Specific Genetic Alterations
SHANGHAI and HONG KONG, April 12, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and onco...
RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue
Independent Data Safety Monitoring Board unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 pneumonia based on review of unblinded safety data from the first 255 treated patients The 464-patient global Phase 2/3 COVID-19 study is ...
Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy® for the Treatment of Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
SHANGHAI, April 9, 2021 /PRNewswire/ -- Everest Medicines
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Chile
* Marks vaccine's first approval in South America, following Mexico, Pakistan, China and Hungary * Safe, stable storage and transportation between 2°C and 8°C, accessible by under-developed regions * 95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination TI...
EyeYon Medical Announces Innovative Medical Device Designation Granted For EndoArt® In China
TEL-AVIV, Israel, April 8, 2021 /PRNewswire/ -- EyeYon Medical, an Israeli start-up company developing a variety of ophthalmic products for vision-threatening conditions, announces today that EndoArt® was granted the Innovative Device Status byChina's Center for Medical Device Evaluation, the ar...
Inmagene R&D Team expands with two new senior members joining the Company
SAN DIEGO and SHANGHAI and HANGZHOU, China, April 7, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") today announced that Dr.Anbo Xiang and Dr.Qian Xu joined the company. As CMO (China) and Senior VP, Operations, Dr. Xiang will be responsible for clinical development, operations, an...
WuXi Biologics Successfully Completed Pre-License Inspection and Routine GMP Inspection by U.S. FDA
WUXI, China, April 7, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has successfully completed both a Pre-License Inspection (PLI) and a routine GMP inspection by the U.S. FDA (FDA). T...
Shanghai Genechem Co., Ltd. (Genechem) Announces Global Collaboration on Bispecific Antibodies
SHANGHAI, April 6,, 2021 /PRNewswire/ -- Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to novel drug target discovery and development of novel therapeutics, today announced the execution of a global collaboration with I-Mab (Nasdaq: IMAB), a Nasdaq-listed global bioph...
Week's Top Stories
Most Reposted
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 279 media titles]
2026-01-01 10:00ACEN completes transition to 100% renewable energy
[Picked up by 274 media titles]
2025-12-29 18:53Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 274 media titles]
2025-12-30 20:12CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 264 media titles]
2025-12-29 09:00ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 261 media titles]
2025-12-29 14:27